Cost-effectiveness of abatacept for moderate-to-severe rheumatoid arthritis.

about

Cost-effectiveness of abatacept for moderate-to-severe rheumatoid arthritis.

Item

http://www.wikidata.org/entity/Q38170177

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Cost-effectiveness of abatacept for moderate-to-severe rheumatoid arthritis.

@en

type

Item

label

Cost-effectiveness of abatacept for moderate-to-severe rheumatoid arthritis.

@en

prefLabel

Cost-effectiveness of abatacept for moderate-to-severe rheumatoid arthritis.

@en

P1476

Cost-effectiveness of abatacept for moderate-to-severe rheumatoid arthritis.

@en

P2093

Carlo A Marra

http://www.w3.org/2001/XMLSchema#string

Kam Shojania

http://www.w3.org/2001/XMLSchema#string

Nicole W Tsao

http://www.w3.org/2001/XMLSchema#string

P2860

Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis

Environmental influences on risk for rheumatoid arthritis

The Stanford Health Assessment Questionnaire: dimensions and practical applications

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

Biologic agents in rheumatoid arthritis: an update for managed care professionals

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes.

Abatacept for rheumatoid arthritis: a Cochrane systematic review.

Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice.

Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting.

P304

9-18

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737167.2014.861742

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-12-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24325566

http://www.w3.org/2001/XMLSchema#string